Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 5 of 14, showing 5 Applications out of 67 total, starting on record 21, ending on 25

# Protocol No Study Title Investigator(s) & Site(s)

21.

ECCT/23/05/05   mRNA-1273-P203
    A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age   
Principal Investigator(s)
1. Videlis Nduba
Site(s) in Kenya
1. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county)
2. KEMRI/USAMRD (Kericho county)
3. Victoria Biomedical Research Institute (Kisumu county)
4. Kenya Medical Research Institute/USAMRU (Kisumu county)
5. KEMRI CMR-Kar Geno Research Centre (Kisumu county)
6. KEMRI/ CDC (Kisumu county)
7. KEMRI (Kisumu county)
8. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county)
9. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county)
 
View

22.

ECCT/23/04/01   mRNA-1273-P203
    A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age   
Principal Investigator(s)
1. Dr Janet Oyieko
Site(s) in Kenya
1. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county)
2. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county)
3. KEMRI/USAMRD (Kericho county)
4. Victoria Biomedical Research Institute (Kisumu county)
5. Kenya Medical Research Institute/USAMRU (Kisumu county)
6. KEMRI CMR-Kar Geno Research Centre (Kisumu county)
7. KEMRI/ CDC (Kisumu county)
8. KEMRI (Kisumu county)
9. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county)
 
View

23.

ECCT/17/06/02   PAINT Study
    A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral-naïve HIV-1 infected adolescents and children aged ≥6 to <18 years   
Principal Investigator(s)
1. Isaac Tsikhutsu
Site(s) in Kenya
1. Kenya Medical Research Institute/Walter Reed Project, HIV Program (Kericho county)
2. KAVI Institute of Clinical Research (Nairobi City county)
 
View

24.

ECCT/11/02/01   Compare the Efficacy and Safety of Gentian Violet to that of Nystatin
    A5265 - A Phase III, Open-Label, Randomized, Assessment-Blinded Clinical Trial to Compare the Safety and Efficacy of Topical Gentian Violet to that of Nystatin Oral Suspension for the Treatment of Oropharyngeal Candidiasis in HIV-1 Infected Participants in Non-U.S. Settings   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
2. KEMRI Walter Reed Project (Kericho county)
 
View

25.

ECCT/22/08/02   AIM-LVRNA009-II_III-01
    A Global Multi-center, Randomized, Blinded, Placebo-controlled Phase 2/3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (LVRNA009) for the Prevention of COVID-19 in Participants Aged 18 Years and Olde   
Principal Investigator(s)
1. Bernhards Ogutu
2. Lucas Otieno
3. Videlis Nduba
4. Bernhards Ogutu
5. Jacqueline Mirera
6. Jacqueline Mirera
Site(s) in Kenya
1. Siaya Clinical Trials Unit (Siaya county)
2. Homa Bay Clinical Trials Unit (Homa Bay county)
3. Ahero Clinical Trials Unit (Kisumu county)
4. CREA-N Machakos (Machakos county)
5. CREA-N Nakuru (Nakuru county)
6. Victoria Biomedical Research Institue (Kisumu county)
 
View